SE0200657D0 - Novel Formulation - Google Patents

Novel Formulation

Info

Publication number
SE0200657D0
SE0200657D0 SE0200657A SE0200657A SE0200657D0 SE 0200657 D0 SE0200657 D0 SE 0200657D0 SE 0200657 A SE0200657 A SE 0200657A SE 0200657 A SE0200657 A SE 0200657A SE 0200657 D0 SE0200657 D0 SE 0200657D0
Authority
SE
Sweden
Prior art keywords
novel formulation
formulation
oral
novel
relates
Prior art date
Application number
SE0200657A
Other languages
English (en)
Inventor
Eva Trofast
Jan Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0200657A priority Critical patent/SE0200657D0/sv
Publication of SE0200657D0 publication Critical patent/SE0200657D0/sv
Priority to PCT/SE2003/000371 priority patent/WO2003074036A1/en
Priority to JP2003572556A priority patent/JP2005519095A/ja
Priority to US10/506,590 priority patent/US20050152847A1/en
Priority to EP03713142A priority patent/EP1487423A1/en
Priority to AU2003217110A priority patent/AU2003217110A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0200657A 2002-03-04 2002-03-04 Novel Formulation SE0200657D0 (sv)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE0200657A SE0200657D0 (sv) 2002-03-04 2002-03-04 Novel Formulation
PCT/SE2003/000371 WO2003074036A1 (en) 2002-03-04 2003-03-03 Novel formulation
JP2003572556A JP2005519095A (ja) 2002-03-04 2003-03-03 新規製剤
US10/506,590 US20050152847A1 (en) 2002-03-04 2003-03-03 Novel formulation
EP03713142A EP1487423A1 (en) 2002-03-04 2003-03-03 Novel formulation
AU2003217110A AU2003217110A1 (en) 2002-03-04 2003-03-03 Novel formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0200657A SE0200657D0 (sv) 2002-03-04 2002-03-04 Novel Formulation

Publications (1)

Publication Number Publication Date
SE0200657D0 true SE0200657D0 (sv) 2002-03-04

Family

ID=20287162

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0200657A SE0200657D0 (sv) 2002-03-04 2002-03-04 Novel Formulation

Country Status (6)

Country Link
US (1) US20050152847A1 (sv)
EP (1) EP1487423A1 (sv)
JP (1) JP2005519095A (sv)
AU (1) AU2003217110A1 (sv)
SE (1) SE0200657D0 (sv)
WO (1) WO2003074036A1 (sv)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004241746A1 (en) * 2003-05-22 2004-12-02 Nycomed Gmbh Salmeterol and ciclesonide combination
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
WO2009026434A1 (en) * 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
DK3354276T3 (da) 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
US20090123551A1 (en) * 2007-11-13 2009-05-14 Meritage Pharma, Inc. Gastrointestinal delivery systems
US20090264392A1 (en) * 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
RU2667644C2 (ru) 2013-04-22 2018-09-21 Тотиги Инститьют Оф Клиникал Патолоджи Противоопухолевое средство

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2588005B1 (fr) * 1985-10-02 1987-12-11 Roquette Freres Maltitol poudre directement compressible et son procede de preparation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
SE9700136D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700134D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9404468D0 (sv) * 1994-12-22 1994-12-22 Astra Ab Powder formulations
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
AU7685200A (en) * 1999-10-12 2001-04-23 Kaken Pharmaceutical Co., Ltd. Powdery inhalational preparations and process for producing the same

Also Published As

Publication number Publication date
US20050152847A1 (en) 2005-07-14
AU2003217110A1 (en) 2003-09-16
WO2003074036A1 (en) 2003-09-12
EP1487423A1 (en) 2004-12-22
JP2005519095A (ja) 2005-06-30

Similar Documents

Publication Publication Date Title
DE60225040D1 (de) Montelukast-granulatformulierung
CO5590918A2 (es) Formulaciones
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
HRP20041152B1 (hr) Farmaceutske formulacije
ATE556704T1 (de) Pulverinhalator-formulierungen
SE0301700D0 (sv) Novel compounds
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
SG153800A1 (en) Pharmaceutical compositions
SE0301653D0 (sv) Novel compounds
WO2002069945A3 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und pde-iv-inhibitoren
TW200517107A (en) Novel formulation
SG148194A1 (en) Compositions for the treatment of affections of the oral cavity and upper respiratory tract
MEP34508A (en) Cladribine formulations for improved oral and transmucosal delivery
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
EE200300501A (et) Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
ITMI20022777A1 (it) Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento.
BR0314129A (pt) Formulações de liberação modificadas de oxcarbazepina e derivados destas
MEP34308A (en) Oral formulations of cladribine
GB0202900D0 (en) Novel formulations of drugs
MXPA06000636A (es) Formulaciones semi-solidas para la administracion oral de taxoides.
ATE353231T1 (de) Pharmazeutische zusammensetzungen
SG144140A1 (en) Emulsifying systems containing azetidine derivatives
DK1567135T3 (da) Tiotropiumholdig pulverformulering til inhalation
SE0103210D0 (sv) New formulations and use thereof
IL168307A (en) Compositions containing roflumilast and (r,r)-formoterol